Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 for moderate-to-severe atopic dermatitis (Phase III)
CTR20232813Phase 3Completed
- Sponsor
- Medigene AG
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in atopic dermatitis (AD), sponsored by Medigene AG. Started Nov 2023; status: completed.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232813.